| Name | Title | Contact Details |
|---|---|---|
Kristin Nevins |
General Counsel | Profile |
La Jolla Pharmaceutical Company is a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases. The Company has several product candidates in development. LJPC-501 is La Jolla`s proprietary formulation of angiotensin II for the potential treatment of catecholamine-resistant hypotension. LJPC-401 is La Jolla`s novel formulation of hepcidin for the potential treatment of conditions characterized by iron overload, such as hereditary hemochromatosis, beta thalassemia, sickle cell disease and myelodysplastic syndrome. LJPC-30S is our next-generation gentamicin derivative program that is focused on therapeutics for the potential treatment of serious bacterial infections as well as rare genetic disorders, such as cystic fibrosis and Duchenne muscular dystrophy.
We offer medical, dental and behavioral health care for Alameda Countys underserved Asian and Pacific Islander community.
Clinical Match™ is a physician-founded community of clinical investigators, patients, volunteers, and providers working towards the advancement of medicine.
The UroLift System is an FDA Cleared, revolutionary minimally invasive treatment of Benign Prostatic Hyperplasia (BPH) or an enlarged prostate.
Pierre Fabre Laboratories is a Saint-Bruno, QC-based company in the Healthcare, Pharmaceuticals, & Biotech sector.